IFNB1 and myeloid sarcoma: Importantly, MS patients treated with various disease-modifying drugs, including IFN-β, natalizumab, and GA, have reduced frequencies of the GM-CSF-producing T cells [125,126], further supporting the rationale of targeting GM-CSF signaling as MS therapy.